Discover
BMS-986165 / BMSLong-Term Safety and Efficacy of BMS-986165 in Subjects with Psoriasis (clinicaltrialsregister.eu) - Nov 26, 2019 - P3; N=1950; Ongoing; Sponsor: Bristol-Myers Squibb International CorporationOtezla (apremilast) / AmgenA Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Nov 25, 2019 - P3b; N=140; Not yet recruiting; Sponsor: CelgeneTaltz (ixekizumab) / Eli LillyA Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) (clinicaltrials.gov) - Nov 25, 2019 - P3; N=1346; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting --> CompletedBMS-986165 / BMSPOETYK-PSO-2: An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis (clinicaltrials.gov) - Nov 27, 2019 - P3; N=1000; Active, not recruiting; Sponsor: Bristol-Myers Squibb; Recruiting --> Active, not recruitingSkyrizi (risankizumab) / AbbVie, Boehringer IngelheimHuge savings as more drugs added to PBS (Nine News) - Dec 1, 2019 - "A series of drugs are being added to the Pharmaceutical Benefits Scheme...Patients with moderate to severe plaque psoriasis...will have access to a new drug Skyrizi (risankizumab)....More patients with severe eosinophilic asthma will also have access to the currently listed asthma medicines Fasenra (benralizumab) and Nucala (mepolizumab) after the access criteria was expanded."Siliq (brodalumab) / Bausch Health, Leo Pharma, Kyowa Hakko KirinSiliq pricing: $42,000/year in US (H.C. Wainwright & Co) - Nov 26, 2019 - A subscription to Thomson ONE is required to gain full access to report 68281151; Page no: 27; REPORT TITLE: "Dynamic drug delivery for Oligos; Initiating at Buy and $8.00 price target”; AUTHOR: Selvaraju, Raghuram, et al; DATE: 11/06/2019Otezla (apremilast) / AmgenOtezla: Newly added patents in Orange Book (Orange Book) - Nov 27, 2019 - Expiry on March 19, 2023 and May 29, 2034 [Screenshot]Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimA Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Nov 29, 2019 - P3; N=157; Active, not recruiting; Sponsor: AbbVie; Recruiting --> Active, not recruiting
